Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8668359 | Journal of Clinical Lipidology | 2018 | 7 Pages |
Abstract
Safety and efficacy observations from the open-label alirocumab expanded use program of very high-risk patients with HeFH and/or CHD and baseline LDL-C of â¥160 mg/dL uncontrolled by maximally tolerated lipid-lowering therapy were consistent with those in the placebo/ezetimibe-controlled ODYSSEY trials.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Charles J. MD, Alan MD, Anne C. MD, James M. PharmD, Louis MD, John MSc, Joseph MD, Andrew MD,